Cargando…
Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms
BACKGROUND: Dose requirements of vitamin K antagonists are associated with CYP2C9 and VKORC1, but, compared to warfarin, less data is available about phenprocoumon. Furthermore, the effects on dose stability and anticoagulation quality are still unclear. METHODS: Aim was to scrutinize phenprocoumon...
Autores principales: | Schneider, Katharina Luise, Kunst, Melanie, Leuchs, Ann-Kristin, Böhme, Miriam, Weckbecker, Klaus, Kastenmüller, Kathrin, Bleckwenn, Markus, Holdenrieder, Stefan, Coch, Christoph, Hartmann, Gunther, Stingl, Julia Carolin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997201/ https://www.ncbi.nlm.nih.gov/pubmed/32047440 http://dx.doi.org/10.3389/fphar.2019.01620 |
Ejemplares similares
-
Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) – study protocol for a pragmatic randomized controlled trial
por: Stingl, Julia Carolin, et al.
Publicado: (2016) -
Potential Drug-Drug Interactions in a Cohort of Elderly, Polymedicated Primary Care Patients on Antithrombotic Treatment
por: Schneider, Katharina Luise, et al.
Publicado: (2018) -
Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters
por: Geisen, Christof, et al.
Publicado: (2010) -
Individualized versus Standardized Risk Assessment in Patients at High Risk for Adverse Drug Reactions (The IDrug Randomized Controlled Trial)–Never Change a Running System?
por: Just, Katja S., et al.
Publicado: (2021) -
Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction
por: Haug, Kari Bente Foss, et al.
Publicado: (2008)